Three wishes for improving clinical drug development in pulmonary fibrosis
Eur Respir J
.
2023 Mar 2;61(3):2202355.
doi: 10.1183/13993003.02355-2022.
Print 2023 Mar.
Author
Harold R Collard
1
Affiliation
1
Medicine and Health Policy, University of California San Francisco, San Francisco, CA, USA harold.collard@ucsf.edu.
PMID:
36863732
DOI:
10.1183/13993003.02355-2022
No abstract available
Publication types
Editorial
Comment
MeSH terms
Drug Development
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Substances
GLPG1205